Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 19/20 | 1.00 |
| ▸ | BRAF | P15056 | 19/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 0.71 |
| ▸ | KIF5B | P33176 | 1/20 | 0.71 |
| ▸ | KDR | P35968 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15051652 | 0.91 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL15052371 | 0.88 | RAF1 (1.00) | RAF1BRAFRETKIF5BKDR | |
| SCHEMBL15052620 | 0.87 | RAF1 (1.00) | RAF1BRAFRETKIF5BKDR | |
| SCHEMBL15052123 | 0.85 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL15052148 | 0.84 | BRAF (1.00) | RAF1BRAFRETKIF5BKDR | |
| SCHEMBL15051367 | 0.84 | BRAF (0.86) | RAF1BRAF | |
| SCHEMBL15051659 | 0.84 | BRAF (1.00) | RAF1BRAFRET | |
| SCHEMBL15077957 | 0.83 | RAF1 (0.76) | RAF1BRAF | |
| SCHEMBL15051359 | 0.83 | RAF1 (1.00) | RAF1BRAFRETKIF5BKDR | |
| SCHEMBL15051738 | 0.82 | RAF1 (1.00) | RAF1BRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785459-B2 | Quinazoline compounds as kinase inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-07-22 | — | — | US | claimed |
| US-20130165458-A1 | QUINAZOLINE COMPOUNDS AS KINASE INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2013-06-27 | — | — | US | claimed |
| US-8785459-B2 | Quinazoline compounds as kinase inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-07-22 | — | — | US | disclosed |
| US-8785459-B2 | Quinazoline compounds as kinase inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-07-22 | — | — | US | disclosed |
| US-20130165458-A1 | QUINAZOLINE COMPOUNDS AS KINASE INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2013-06-27 | — | — | US | disclosed |
| US-20130165458-A1 | QUINAZOLINE COMPOUNDS AS KINASE INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165458-A1 | QUINAZOLINE COMPOUNDS AS KINASE INHIBITORS | CNKSR1, NRAS, HRAS | RAF1 10/4885BRAF 8/4885RET 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.